New driver of breast cancer discovered
As cholesterol is metabolized, a potent stimulant of breast cancer is created—one that fuels estrogen receptor (ER)-positive breast cancers, according to new research.
Diagnosis & Disease Information
Luminal breast tumors have enhanced response to antiestrogen therapy
The luminal breast cancer subtype has enhanced expression of the ERBB3 oncogene, and depleting the ERBB3 protein with an antibody promotes cancer cell death and decreases tumor growth in vitro, according to a new study.
BH3 mimetics improved tamoxifen therapy in breast cancer
The addition of BH3 mimetics to standard tamoxifen treatment improved the effectiveness of hormone therapy in luminal B cancers, an aggressive subtype of ER-positive breast cancer.
Osteoporosis drug stops growth of breast cancer cells, including resistant cells
A drug approved in Europe to treat osteoporosis has been shown to stop the growth of breast cancer cells, according to a new study.
Fat-metabolism genes may predict breast cancer down to the ER subtype
Lipid-metabolism genes are potential biomarkers of estrogen-receptor (ER)-specific breast cancer risk, researchers have found.
Model underestimates breast cancer risk for some African-American women
A breast cancer risk model for African-American women underpredicted individual risk and risk of estrogen receptor (ER)-negative disease.
Clinical benefit seen when investigational agent is combined with letrozole
The combination of the investigational agent PD 0332991 and letrozole significantly improved median progression-free survival in patients with advanced estrogen receptor-positive breast cancer.
- Loading...
Loading...
Loading... 
Loading...